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ABSTRACT 
Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder characterized by early 
proximal muscle weakness and progressive loss of muscle function that primarily affects males. 
Although there is currently no cure for the disease, there is ongoing research into treatments to 
slow the disease progression, which could impact overall quality of life (QoL) for boys and men 
with DMD. Many early studies on QoL in DMD were conducted using parent-proxy reports but 
more recent research has suggested that boys with DMD might perceive their QoL differently than 
their caregivers. The purpose of this study was to determine if parents of adolescents with DMD 
perceive their child’s QoL the same as the boys perceive their own QoL and to determine if specific 
aspects of DMD (glucocorticoid use, loss of ambulation, noninvasive respiratory support, and 
inability to self-feed) affect these perceptions. This study analyzed data from PedsQLTM 4.0 
Generic Core Scale surveys and the PedsQLTM 3.0 Neuromuscular Module administered to 
participants ages 11-17 years old and their caregivers through the Cooperative International 
Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS). Overall, 
parents reported lower physical QoL scores (p<0.003) and higher emotional (p=0.049), social 
(p<0.001), and school-functioning (p<0.022) QoL scores compared to their sons. Older 
participants and their caregivers both reported higher physical QoL scores than younger 
participant/parent-proxy reports (p=0.017, p=0.035). Participants taking glucocorticoids reported 
lower physical QoL than participants not taking glucocorticoids (p<0.001). There was no 
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difference in participant reported total QoL before and after both loss of ambulation and starting 
non-invasive respiratory support. The results suggest that adolescents with DMD have more 
positive perceptions regarding their physical QoL and more negative perceptions regarding their 
psychosocial QoL when compared to their parents, indicating a difference between adolescent 
experiences and parent perceptions.  The results also suggest that the PedsQLTM 4.0 survey may 
not appropriately capture physical QoL in adolescents with DMD.  Improving population health 
and QoL is an important public health goal, and the results of this study provides information that 
may help guide interventions to improve the QoL for adolescents with DMD.  
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1.0  INTRODUCTION 
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disease causing progressive 
loss of muscle function primarily in boys1. It is caused by mutations in the DMD gene which codes 
for the dystrophin protein, an important protein in muscle function2,3. Without intervention, boys 
with DMD experience loss of ambulation during early adolescence and premature death in early 
adulthood, often due to cardiomyopathy or respiratory failure1,4,5. Current interventions, such as 
glucocorticoid use and respiratory support, can delay the onset of significant disease milestones 
and increase the lifespan for boys with DMD. Although there is currently no cure, there is ongoing 
research into pharmaceuticals and other interventions that might slow disease progression, increase 
life-span, and improve overall quality of life (QoL).4,6  
The World Health Organization (WHO) defines QoL as “an individual’s perception of their 
position in life in the context of the culture and value systems in which they live and in relation to 
their goals, expectations, standards and concerns.”7,8 In recent years, pharmaceutical and clinical 
research on DMD have become increasingly interested in assessing health-related quality of life 
(HrQoL)—the subset of quality of life due to one’s state of health.9 Given the significant impact 
of DMD on overall health, it is important to assess how boys with DMD perceive their own HrQoL 
to determine if new interventions impact HrQoL for boys and men with DMD, and to determine 
new potential approaches to improve HrQoL. Early research on this topic depended on parent-
proxy reports to assess QoL in DMD. However, more recent research suggests that children with 
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DMD perceive their own QoL differently than their parents perceive it.10–16 This project is intended 
to help determine what differences, if any, exist between child and parent-perceived QoL in DMD. 
The specific aims are as follows:  
1. To determine if caregivers of boys with DMD perceive their child’s QoL the same as 
the children perceive their own QoL.  
2. To determine if steroid use, time at loss of ambulation (LoA), utilization of non-
invasive respiratory support, and inability to self-feed:  
• correlate with perceived QoL for boys with DMD in this study cohort. 
• correlate with caregiver perceptions of QoL of boys with DMD.  
• correlate with differences between caregiver and participant reported QoL 
(if any). 
We hypothesized that there would be differences between participant and parent-proxy 
reported HrQoL. We also hypothesized that there would be differences in both participant and 
parent-proxy reported QoL before and after participants reached specific disease milestones, and 
that participants using steroids would report higher HrQoL than participants not taking steroids.  
This project analyzed data related to HrQoL collected as part of the Cooperative 
International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS). 
CINRG is an academic network of sites around the world who have partnered together to research 
neuromuscular diseases and improve patient QoL.17,18 The CINRG DNHS is the most extensive 
DMD natural history study to date. From 2006-2016, the network recruited and followed over 400 
boys and men ages 2-30 with DMD from eight different countries and collected phenotypic, 
genotypic, and biomarker data.5 Along with physical assessments, participants in the study 
completed multiple age-specific, validated QoL surveys to assess QoL in DMD. One such survey 
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was the Pediatric Quality of Life Questionnaire (PedsQLTM) 4.0 General Core Scale.5,19,20 This 
scale was administered to adolescents ages 11-17 at every study visit. Caregivers of these 
adolescents simultaneously completed a parent-proxy version of the form to report their perception 
of their child’s QoL.5 Starting in 2012, the PedsQLTM 3.0 Neuromuscular Module (NMM) was 
also administered to adolescents ages 11-17 and their parents.5 This project compares the 
participant and parent-proxy results of the PedsQLTM Versions 3.0 and 4.0 both overall and at 
significant disease milestones (LoA, inability to self-feed) to determine if there are differences 
between participant and parent-proxy reported QoL and to determine factors that might affect 
perceived QoL.  
This project is one of the few to analyze QoL in adolescents with DMD. Most studies 
investigating QoL in DMD have either focused on children or have grouped adolescents with 
children ages 10 years of age and younger in the analysis, and only a handful of studies have 
isolated adolescents for analysis.11,21,22 Consequently, there is limited data regarding QoL in 
adolescents with DMD. This project will help elucidate how adolescents with DMD perceive their 
own QoL and how their perceptions compare to caregiver perceptions. This study also investigated 
QoL before and after the onset of disease milestones. There is limited research regarding the impact 
of disease milestones on QoL in DMD. The research thus far has primarily compared boys who 
had reached the milestone by the time of survey completion to boys who had not reached the 
milestone.11,23–25 The longitudinal nature of the data collected through the CINRG DNHS allows 
this study to analyze QoL immediately before and after the onset of each milestone which provides 
a more direct examination of the impact of disease milestones on QoL in DMD. The results of this 
study may help health professionals and genetic counselors better educate parents of children with 
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DMD regarding current and future QoL concerns and will provide useful information for rare-
disease researchers wanting to incorporate QoL as an endpoint in their clinical research trials.  
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2.0  LITERATURE REVIEW 
2.1 DUCHENNE MUSCULAR DYSTROPHY (DMD) 
DMD is a rare neuromuscular disorder categorized by early, proximal muscle weakness and 
progressive loss of muscle function that primarily occurs in males.1 It occurs in approximately 
1/5100 to 1/9330 live births, making it the most common cause of muscular dystrophy.6,26  
DMD is caused by mutations in the DMD gene located on the X-chromosome.2,3,27 The 
DMD gene codes for the dystrophin protein, a protein that is involved in stabilizing the skeletal 
muscles.2,3 Mutations that lead to a truncated dystrophin protein, such as large deletions and 
frameshift mutations leading to premature stop codons, cause DMD.28,29 Other mutations in the 
DMD gene that do not lead to a truncated protein can cause a similar neuromuscular disease, 
Becker muscular dystrophy (BMD).30,31 BMD is also characterized by progressive proximal 
muscle weakness, but the clinical course of disease is slower and less severe than that of DMD.32,33  
2.1.1 Clinical Course of DMD 
DMD usually presents in boys between 3-5 years of age.1,30 Initial symptoms include 
delayed motor milestones, clumsiness, abnormal gait, and difficulty keeping up with peers. 1,30 
Other early signs of DMD include elevated serum creatine kinase (CK) levels, calf hypertrophy, 
and a Gower sign.1,30 The Gower maneuver involves first getting on one’s hands and feet and then 
walking the hands up the legs to stand. Because boys with DMD experience proximal muscle 
weakness, they use this unique position to stand from sitting on the floor.4,6 After DMD is 
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suspected in an individual, the diagnosis can be confirmed with DMD deletion/duplication testing 
followed by gene sequencing if a large deletion or duplication is not identified. If DMD is strongly 
suspected but genetic testing does not identify a mutation, then a muscle biopsy can be performed 
to assess dystrophin protein levels.4,6  
As boys with DMD age, they experience progressive loss of proximal muscle function. 
They begin to have difficulty walking followed by reduced arm strength and mobility.1 Over time, 
they eventually lose ambulation and require a wheelchair. If left untreated, most boys transition to 
the wheelchair during their early teenage years.5,6,27 Current treatment and management options 
can delay loss of ambulation, but do not prevent it.4,27   
Boys with DMD have variable intellectual delays and may also fall on the autism spectrum. 
Many also have behavior concerns such as hyperactivity and attention deficit disorder.34 Other 
symptoms of DMD include pulmonary, cardiac, and musculoskeletal complications, as well as 
swallowing difficulties.6,35 Almost all boys with DMD develop restrictive lung disease which can 
later cause respiratory insufficiency.1 Obstructive sleep apnea is another pulmonary complication 
associated with DMD, affecting up to 63% of boys by young adulthood.36–38 Along with 
pulmonary complications, boys with DMD develop cardiac concerns, such tachycardia, 
arrhythmias, and dilated cardiomyopathy.1,39,40 Musculoskeletal complications include joint 
contractures, bone fractures, and scoliosis. As the disease progresses, boys with DMD can 
experience difficulties chewing and swallowing, which can affect nutrition if not managed 
appropriately.6 Death occurs between the second and fourth decades of life, most often due to 
respiratory failure or cardiac arrest.4,5   
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2.1.1.1 Significant Disease Milestones 
  
 
Figure 1: Timeline of Disease Milestones in DMD with Glucocorticoid Treatment 
 
As boys with DMD age, they experience significant clinical milestones—points that mark 
disease progression. Figure 1 outlines the timing of some of these important milestones as they 
occur today where glucocorticoid treatment is the standard of care for boys with DMD.4,27,41 
Ambulation milestones include the inability to stand up from the floor, the inability to climb stairs, 
and the complete loss of ambulation.5,27 Another major milestone is the inability to self-feed. This 
occurs in early adulthood when the individual loses the ability to lift their arms to feed 
themselves.5 At or shortly after losing the ability to self-feed, boys with DMD require use of non-
invasive nocturnal ventilation as respiratory complications progress.5,27 The last disease milestone 
is, unfortunately, early death.  
2.1.2 Treatment and Management 
2.1.2.1 Glucocorticoids 
Glucocorticoids are a type of steroid hormone that are used to slow the progression of 
DMD-related symptoms and are considered standard of care for DMD. Prednisone and Deflazacort 
are two types of glucocorticoids commonly used to treat boys with DMD. In February of 2017, 
Deflazacort was approved by the Food and Drug Administration (FDA), making it the first and 
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only FDA approved glucocorticoid to treat DMD in the United States.42 A number of studies have 
consistently demonstrated that glucocorticoids increase the time to loss of ambulation, reduce 
disease symptoms (such as scoliosis, muscle weakness, and respiratory symptoms), delay the onset 
of other disease milestones, and prolong life.41,43,44 However, boys using glucocorticoid treatment 
also experience significant side effects, including obesity, reflux, osteoporosis, vertebral fractures, 
delayed puberty, growth restriction, immunosuppression and cataracts.27,45–47 Behavioral problems 
such as aggression, hyperactivity, mood-swings, and depression are also frequent.46,47 Given the 
side-effects, it is recommended that boys do not begin steroids until their motor skills plateau 
although some clinicians have studied early use of steroids.6,27,48  
2.1.2.2 Symptom Management 
Aside from glucocorticoids, several other options are available for managing the symptoms 
of DMD. Assistive devices, such as shoe inserts, braces, and supportive standing devices, help 
boys continue to ambulate as their muscles weaken.6 Eventually, wheelchairs are used for mobility. 
Physical therapy helps to retain full range of motion in the joints and prevent joint contractures. 
Surgery may be considered to treat certain joint contractures, but recent management guidelines 
recommend surgery only on an individual basis.6 To manage cardiac symptoms, boys with DMD 
can take heart failure medications, including ACE inhibitors and beta blockers.4,35 Both non-
invasive and invasive ventilation devices may be used to manage respiratory disease and sleep 
apnea, depending on the severity of disease—although non-invasive devices are preferable.35,49 
Bone health is maintained using Vitamin D and/or Calcium supplements as needed.35 Boys with 
DMD follow with a multidisciplinary team to manage and treat their symptoms. 
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2.1.2.3 New Therapeutics   
There are several active clinical trials and research studies investigating novel therapeutics 
for DMD. A number of these research drugs will not be curative, but aim to reduce the severity of 
disease to that of a BMD phenotype.4 Examples of experimental therapeutics include exon-
skipping, nonsense suppressor, and muscle regeneration therapies.4 Exon-skipping therapeutics 
block translation of particular exons in the DMD gene to allow the production of a functional, 
albeit incomplete, dystrophin protein.50,51 Although the resulting protein is shortened, it is 
predicted to function well enough to slow down the natural course of disease. In September 2016, 
Eteplirsen became the first exon-skipping drug approved by the United States FDA to treat boys 
with DMD.51 This therapeutic is aimed to treat boys whose mutations are amenable to the skipping 
of exon 51 (approximately 14% of boys with DMD).51 The FDA granted accelerated approval to 
Eteplirsen, a decision that has proved to be controversial, particularly given the limited possible 
efficacy and sample size of the cohort in the Phase II trial.52 Time and monitoring will provide 
more evidence regarding the effectiveness of this drug.  
Another active area of research for DMD treatment is gene therapy using vectors to deliver 
functional DMD genes to muscle cells. The cells can  theoretically incorporate the functional gene 
into their genome and begin to produce a normal dystrophin protein. Early research studies were 
complicated by adverse immune responses to the vectors used to deliver the functional dystrophin 
gene, .52,53 Despite these initial set-backs, gene-therapy has now entered into clinical trials, and in 
January 2018, the first dose of gene therapy was administered to a boy with DMD. If successful, 
gene therapy has the potential to cure DMD. 
There are a wide array of other therapeutics under investigation that are intended to treat 
boys with DMD regardless of mutation status. Some of these therapeutics are posed as an 
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alternative to glucocorticoids and claim to slow disease progression without the significant side-
effects of current steroid treatment.6,54 Other interventions aim to upregulate utrophin—a 
dystrophin paralogue expressed primarily in fetal development.4,6,55 Since utrophin has a similar 
structure and function to dystrophin, increasing utrophin expression could help compensate for the 
lack of dystrophin protein and reduce the severity of disease.55 
2.2 THE COOPERATIVE INTERNATIONAL NEUROMUSCULAR RESEARCH 
GROUP DUCHENNE NATURAL HISTORY STUDY 
2.2.1 The Cooperative International Neuromuscular Research Group (CINRG) 
CINRG is a network of over 20 academic and research sites across the world who have 
partnered together to perform clinical research trials for neuromuscular disorders and improve the 
quality of life for individuals with these diseases.17,18 Given the rarity of neuromuscular diseases 
and the need for increased sample sizes to properly research therapeutics, the CINRG network was 
established in 2000 to allow for multi-site involvement in the study of promising new treatment 
options for neuromuscular disorders. So far, the network has recruited over 1,300 participants in 
over 20 studies, which has resulted in over 25 publications.18  
2.2.2 Duchenne Natural History Study (DNHS) 
The CINRG DNHS is a prospective, longitudinal research study performed by the CINRG 
network to study the natural history of DMD.5 From 2006 to 2016, CINRG sites across the world 
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recruited and followed over 400 boys with DMD. The  enrollment number and length of the study 
make it the most extensive DMD natural history study to date.5 A subset of data collected through 
the CINRG DNHS was analyzed to conduct this thesis project.  
2.2.2.1 Purposes 
The CINRG DNHS gathered phenotypic, genotypic, and biomarker outcomes data to 
explore the natural history of the disease, study the effects of long-term glucocorticoid use, and 
assess the impact that DMD has on individuals and families. The study also aimed to investigate 
genetic modifiers of DMD, assess novel outcome measures, and identify new serum biomarkers 
for the disease.5 The phenotypic data collected through this study created a normative data set that 
could be used as a “control group” in future clinical research trials.5 
2.2.2.2 Study Enrollment and Timeline  
Enrollment for the CINRG DNHS began in 2006 and the study closed in 2016. Over this 
10-year timespan, more than 400 boys ages 2-30 years old with DMD were enrolled from eight 
different countries: Argentina, Australia, Canada, India, Israel, Italy, Sweden, and the United 
States.5,18  
Boys were eligible to participate in the study if they were between 2-30 years old and had 
a definitive diagnosis of DMD. A definitive diagnosis was defined as the presence of one of the 
following: 1) clinical features of the disease and immunofluorescence or immunoblot test 
demonstrating complete lack of dystrophin protein, 2) genetic confirmation of an out-of-frame 
single or multi-exon deletion in the DMD gene, 3) clinical features of the disease and genetic 
confirmation of a small variant (point mutation, insertion, etc.) that likely produces a truncated 
protein, or 4) clinical features of the disease and an older brother with a confirmed diagnosis of 
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DMD. Boys ages 5-30 were also eligible for enrollment if they had clinical features of DMD and 
evidence supporting a dystrophinopathy. Acceptable evidence included: 1) a DMD gene mutation, 
2) a muscle biopsy showing reduced or absent dystrophin protein, or 3) CK levels elevated five 
times higher than normal and an X-linked family member (maternal uncle, maternal cousin, etc.) 
with a confirmed diagnosis of DMD.5 
Boys were excluded from the study if: 1) they were ambulatory after their 13th birthday 
and had never used steroids, 2) they were ambulatory after their 16th birthday while using steroids, 
or 3) they demonstrated noncompliance with the study protocol.5 The first two exclusion criteria 
were included to ensure that boys with BMD or milder forms of DMD were not included in the 
study.  
Upon enrollment, all study participants completed a baseline assessment and had follow-
up assessments at months 6, 12, 18, and 24. Ambulatory participants completed two extra study 
visits at months 3 and 9. After the 24-month visit, participants returned annually for continued 
assessments, culminating in at least 5 years of follow-up data per participant some with 10 years.5 
2.2.2.3 Measurements 
A variety of measurements and medical history were taken at each study visit, including 
general health status, muscle strength and function, pulmonary function, cardiac function, and 
HrQoL measures.5 Assessments from this study were used to determine when participants began 
using glucocorticoids and reached the disease milestones assessed in this project (LoA, loss of 
self-feeding, and use of non-invasive respiratory support). Details regarding every measurement 
used in this study is outlined in McDonald et al. 2013. Surveys administered through this study 
were also used to assess participant and caregiver perceptions of participant QoL. For more 
information on the HrQoL measures, see Section 2.3.2.1.  
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Glucocorticoid use, LoA, and use of non-invasive respiratory support were established 
using health status data. Health status was assessed at each study visit with a physical exam and 
review of medical information as provided by the participant or the caregiver of the participant. 
Along with demographic and molecular diagnostic information, information about the 
participant’s medical history was collected. This information included history of glucocorticoid 
(steroid) use, specialty medical services, use of assistive devices, and school support received by 
the participant.5  
Muscle strength and function were measured using both timed and untimed assessments. 
One such untimed assessment is the Brooke Upper Extremity Grade.5,56 The Brooke Upper 
Extremity Grade is a validated measurement of upper extremity function used to evaluate disease 
progression in DMD.  Function is rated on a scale of 1 to 6, with 1 being no loss of upper extremity 
function and 6 being complete loss of upper extremity function.56 Data from this scale was used to 
quantify inability to self-feed in this project.  
2.3 QUALITY OF LIFE IN DMD 
There has been an increased interest within the last decade in assessing QoL in boys with DMD. 
In 1995, the WHO defined QoL as a person’s “perception of their position in life in the context of 
the culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns.”7,57 In other words, QoL is how an individual feels regarding the way in 
which they are living. There are many factors that affect overall QoL. One of these factors is one’s 
HrQoL. HrQoL is the perceived quality of life based on one’s health status, and is defined by the 
Center for Disease Control and Prevention (CDC) as one’s “perceived physical and mental health 
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over time.”8 HrQoL captures the domains of the WHO 1984 definition of health that can affect 
overall quality of life—physical, mental (psychological), and social health.8,9 HrQoL and general 
QoL measures are now measured frequently in research and clinical trials, especially those 
investigating chronic, progressive diseases like DMD, since these measures can capture 
information that might be lost with clinical markers.58,59 The FDA even recommends incorporating 
QoL measures into clinical research trials and supports the use of these measures in DMD 
research.58,60 Because of this, QoL has become an important measurement in clinical research on 
DMD. This thesis project will contribute to the ongoing research of QoL in DMD.  
2.3.1 QoL in Pediatric Neuromuscular Disorders Populations 
Neuromuscular disorders (NMDs) are diseases that affect both the nervous system and 
muscular system. Muscular dystrophies like DMD and BMD are one kind of NMD. Other types 
of NMDs include myopathies, motor neuron diseases (like Spinal Muscular Atrophy), and 
peripheral nerve diseases (like Charcot Marie Tooth disease).61 
2.3.1.1 QoL in Pediatric NMDs Compared to Unaffected Peers 
Generally, individuals with pediatric NMDs report lower overall QoL compared to healthy 
peers.62 Both physical and psychological HrQoL appear to be negatively impacted in this 
population.24,62,63 Interestingly, one study found that Dutch children with muscular dystrophies 
actually reported increased physical HrQoL compared to healthy peers.64 This study included 
participants with muscular dystrophies as well as female carriers of DMD or BMD. Although 
female carriers of these disorders can experience musculoskeletal and cardiac symptoms, they 
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generally are not as physically affected as males with DMD/BMD.65,66 This could be one 
explanation for the unexpected results of that study.  
2.3.1.2 QoL in DMD Compared to Other Neuromuscular Disorders 
Very few studies have directly compared the QoL for boys with DMD to those with other 
NMDs. The most comprehensive analysis compared QoL between participants with over 15 
different kinds of NMDs. Participants with DMD, BMD, congenital muscular dystrophy, and 
spinal muscular atrophy reported significantly reduced physical HrQoL compared to participants 
with other NMDs, although overall QoL was not significantly different between the groups.24 This 
implies that boys with DMD are impacted more by their physical manifestations than individuals 
with most other NMDs. Another study comparing boys with BMD to boys with DMD found that 
boys with BMD reported increased HrQoL compared to boys with DMD.64 This provides further 
evidence that boys with DMD have reduced QoL compared to other NMDs.  
2.3.2 Measuring QoL in DMD Populations 
2.3.2.1 Validated Surveys 
A number of validated surveys that measure QoL and HrQoL in children, adolescents, and 
adults have been established for use in DMD cohorts. The CINRG DNHS utilized six such surveys: 
1) the PedsQLTM Version 4.0 Generic Core Scale10,19,20, 2) the PedsQLTM Version 3.0 NMM10, 3) 
the Pediatric Orthopedic Society of North America (POSNA) Pediatric Musculoskeletal 
Functional Health Questionnaire (also referred to as the Pediatric Outcomes Data Collection 
Instrument or PODCI)67,68, 4) the WHO QoL-BREF57,69, 5) the Life Satisfaction Scale for 
Adolescents (LSI-A)70,71, and 6) the Medical Outcome Study 36-item Short-Form Health 
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Survey.5,72 Other commonly used surveys include the KIDSCREENTM-52 questionnaire, the 
Quality of Life in Neurological Disorders (Neuro-QOL) and the Patient-Reported Outcomes 
Measurement Information System (PROMIS), all of which were developed to evaluate HrQoL in 
individuals with chronic illnesses.73–76 The PedsQLTM Generic Core Scale was developed for use 
in both healthy and ill children and adolescents. 10,19,20 The PODCI, on the other hand, is more 
specialized, and assesses HrQoL in relation to musculoskeletal health in children and 
adolescents.11 The PedsQLTM Neuromuscular module is another specialized survey for children 
and adolescents used to analyze HrQoL in relation to neuromuscular health.10 The WHO-QoL-
BREF, the LSI, and the 36-item Short-Form Health Survey were developed to assess QoL in 
adolescents and adults. 57,69,72 Of all of the QoL surveys available to assess QoL in boys with DMD, 
the PedsQLTM 4.0 Generic Core Scale is one of the most frequently used surveys, particularly in 
the United States.12 This thesis utilized data collected through the PedsQLTM 4.0 Generic Core 
Scale in the CINRG DNHS so that the results will be comparable to previous research. This project 
also analyzed data from the PedsQLTM  3.0 NMM since this survey was developed for use in 
neuromuscular disease population and may better represent QoL in DMD.  
2.3.3 DMD QoL Throughout the Lifespan 
Within the last decade—as the life expectancy of boys with DMD has risen and clinical 
research trials have begun incorporating QoL surveys into their trials—researchers have become 
increasingly interested in how boys with DMD perceive their own QoL.12 Researchers have sought 
to compare the QoL of boys with DMD to that of healthy peers. There is also interest in how 
children with DMD perceive their QoL over time and compared to adolescents and adults with the 
disease. Although it is easy to assume that individuals with a debilitating disease like DMD would 
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have reduced QoL that worsens with disease severity, research studies on the subject have 
produced different results regarding how QoL is impacted in this population.62,77,78  
2.3.3.1 Pediatric DMD QoL  
Many early studies on child QoL in DMD were conducted using parent-proxy reports, 
which may or may not be an accurate representation of child-perceived QoL (this topic is explored 
further in Section 2.3.6.).11,12,79,80 One of the first studies that directly assessed child and 
adolescent-reported QoL in DMD was completed by Uzark et al. in 2012. They surveyed 117 boys 
with DMD ages 6-18 years old using the PedsQLTM Versions 3.0 and 4.0 in an effort to assess how 
the boys perceived their own HrQoL. Their results showed that, on average, children with DMD 
reported lower QoL compared to data collected from healthy peers.11 Other studies have replicated 
the conclusion that overall QoL is reduced in children with DMD compared to healthy 
controls.10,22,81 However, recent research contradict these findings and suggest that children with 
DMD do not perceive a significant difference in QoL compared to healthy children of the same 
age.21,82,83  
Particular aspects of HrQoL for children with DMD may be impacted to a greater degree 
or in different ways than others.12 HrQoL is often broken down in to three domains: physical, 
psychological, and social. Studies have repeatedly demonstrated that children with DMD report 
reduced levels of physical HrQoL compared to healthy peers, even when the average QoL is not 
significantly impacted.10,11,21,68,80,82,83 Analysis regarding psychological HrQoL in pediatric DMD 
participants is less consistent, with some studies concluding that boys with DMD have reduced 
psychological and HrQoL compared to healthy peers10,11,21,80 and others concluding that there is 
no statistical difference for this age group.82,83 Similar findings exist for social HrQoL. Zamani et 
al. reported in 2016 that children with DMD report lower HrQoL in regards to “friends” when 
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compared to healthy controls, although there was no difference in overall reported QoL.83 Findings 
from previous studies, however, conflict with this result, and often only demonstrate a reduced 
social HrQoL in the pediatric DMD population when the overall QoL is also decreased.11,22,82 If 
children with DMD do have a lower psychological and social HrQoL when compared to healthy 
peers, then the difference does not appear to be as large as the physical HrQoL domain.12   
2.3.3.2 Adolescent and Adult DMD QoL  
Adolescents are often grouped with children when investigating overall QoL, and 
therefore, the research on adolescent QoL conflicts just as described above for pediatric 
participants. Less is known regarding the general QoL in adults with DMD, perhaps due to the fact 
that many clinical and research trials currently using QoL surveys do not recruit adults with DMD. 
A recent study conducted in the Netherlands concluded that adults with DMD have a lower general 
QoL compared to healthy adults, although 73% of participants rated their overall QoL as either 
“good” or “very good”.84  This contrasts to a 2005 study performed by Kohler et al. which found 
that overall QoL was not significantly different between healthy adults and adults with DMD.23 
Landfelt et al. 2016 found that individuals with DMD in later stages of disease reported 
significantly lower total QoL than those in earlier stages.16 Since adults with DMD are at a later 
stage of disease, this could indicate that adults with DMD have reduced QoL compared to children 
with DMD.  
Like their pediatric counterparts, adolescents and adults with DMD also have reduced 
physical HrQoL compared to healthy peers.10,11,21,68,80,82–84 Physical HrQoL also correlates with 
disease severity (and thus age) in DMD.11,23,82 This is the only domain of HrQoL that consistently 
correlates with disease severity.   
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Interestingly, psychological HrQoL does not seem to be negatively impacted by age—
adolescents and adults with DMD have even reported higher psychological HrQoL compared to 
children with DMD.11,22 Adolescents and adults with DMD also do not differ significantly in this 
domain compared to healthy controls, suggesting possible improvement of psychological HrQoL 
over time.22,84 As boys with DMD age, they start to engage less in social interactions and activities 
than younger children with DMD. Despite this decrease in social engagement, social HrQoL does 
not seem to be significantly affected.21,23 
2.3.4 Factors Affecting QoL  
This section provides an overview of some factors that may affect QoL for individuals with 
DMD. It is important to note that there are a variety of other factors that could also impact QoL 
but for the purposes of this thesis, the focus will be on physical factors and interventions that 
correlate with and/or affect the onset of disease milestones since disease milestones mark times of 
significant physical and medical changes for boys with DMD.  
2.3.4.1 Glucocorticoid Use and QoL 
As described in Section 2.1.2.1., glucocorticoids reduce DMD disease symptoms and delay 
the loss of motor ability. Given the fact that glucocorticoids delay severe disease symptoms, and 
that reduction in disease severity is associated with increased physical HrQoL, it would stand to 
reason that boys with DMD who are taking glucocorticoids could have increased physical HrQoL 
compared to boys with DMD of the same age who are not taking glucocorticoids. Only a handful 
of studies have directly compared child-reported HrQoL between boys with DMD on and off 
steroids. Bray et al. surveyed boys with DMD using the PedsQLTM General Core Scale and 
 20 
compared the results between boys taking glucocorticoids and boys not taking glucocorticoids. 
Boys with DMD who were on glucocorticoids reported significantly increased physical HrQoL 
compared to the steroid-free group.14 There was also no difference in psychological HrQoL 
between the two groups. Uzark et al. compared both parent-proxy and child-reported QoL between 
children with DMD on and off glucocorticoids. They determined that parents of children with 
DMD who are taking glucocorticoids report increased child activity levels than parents of children 
with DMD who are not taking glucocorticoids; however, child self-reports did not replicate this 
difference.11 There was also no significant difference in overall psychological HrQoL between the 
two groups as reported by child or parent-proxy report, although boys taking glucocorticoids 
reported less worry than boys not taking glucocorticoids.11  
2.3.4.2 QoL at Disease Milestones   
It is hypothesized that QoL may be affected by the onset of significant disease milestones, 
such as loss of ambulation, use of noninvasive respiratory support, and inability to self-feed. Some 
studies have investigated possible interactions between these milestones and reported HrQoL in 
DMD, but no causal relationships have been identified.  
Multiple studies have demonstrated that boys with DMD who use wheelchairs (and have 
thus lost the ability to ambulate independently) report significantly lower physical HrQoL levels 
than boys who do not require wheelchairs.10,80 No significant differences in child-reported 
psychological HrQoL have been identified between these two groups. Although boys using 
wheelchairs report lower physical HrQoL than ambulatory boys, studies have not determined if 
the onset of wheelchair use correlates with a reduction in individual HrQoL. 
Studies conflict as to whether HrQoL is affected when boys with DMD require noninvasive 
respiratory support. Mah et al. surveyed children with neuromuscular disorders, including DMD, 
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using the PedsQL Generic Core Scale to see if at-home respiratory support affected QoL.24 This 
study found that individuals with neuromuscular disease who require at-home respiratory care 
report a significantly lower HrQoL than those with neuromuscular disease who do not require 
respiratory care.24 Because other neuromuscular diseases were included in this study, it is unclear 
whether these results apply specifically to the DMD community. Conversely, Kohler et. al. 
surveyed boys with DMD using the 36-item Short-Form Health Survey and found that use of 
respiratory support did not significantly affect the reported HrQoL.23 Of note, this study surveyed 
children using a survey developed for adults, so again, it is unclear whether the results provide an 
accurate assessment of the pediatric DMD population.  
Since most of the QoL studies in the DMD population have surveyed children and 
adolescents, there is little data regarding whether the inability to self-feed affects HrQoL. Houwen-
van Opstal et al. analyzed the relationship between HrQoL and the Brooke scale and found no 
significant correlation between the two.82 This may suggest that severely reduced upper arm 
mobility (which would indicate an inability to self-feed) does not correlate with reduced HrQoL. 
2.3.4.3 Limitations of DMD HrQoL Studies 
One of the primary limitations of studies investigating HrQoL in DMD is reduced sample 
size.12 Aside from a study published by Landfelt et al. in 2016 which surveyed over 700 boys and 
men with DMD, most studies in this area have sample sizes of 100 boys or less.12,16 DMD is a rare 
disease, and therefore, it can be difficult to gather adequate sample sizes to perform these studies. 
Low sample sizes increase effects from random error and can be a possible explanation for some 
discrepancies between studies. Another significant limitation is the use of different survey 
methods.12 Although the variety of available surveys allows for descriptions of different aspects 
 22 
of HrQoL, it can make it difficult to directly compare study results, especially since surveys do 
not always include the same items for analysis.12   
2.3.5 Caregiver Perceptions of DMD QoL  
Parent-proxy measures have often been used when evaluating QoL in DMD.11,12,79,80 These 
measures consist of asking parents or other primary caregivers to report on how they think their 
child with DMD perceives his QoL. It is an indirect measure of QoL since the boys themselves are 
not directly reporting. Although this method is convenient—caregivers are sometimes more 
willing and able to complete written surveys than children with DMD—there is debate as to 
whether parent-proxy measures are accurate representations of patient-perceived QoL in DMD. 
To assess possible differences between child-reported and caregiver-reported QoL in 
DMD, researchers administer the same survey to both the child and the caregiver and analyze the 
responses. The results from these studies reveal that caregivers generally report lower overall 
HrQoL than the boys do, indicating that caregivers perceive a lower QoL for the boys than the 
boys themselves perceive.10–16 The discrepancy between parent and child-reported HrQoL is not 
consistent, however, with some studies indicating poor agreement10,11 and others indicating 
moderate to high agreement.13,15,16 Interestingly, Cremeens et al. reported very poor agreement 
between parent-proxy and child-reported QoL, but parents in their study rated their child’s QoL 
significantly higher than the child did, not lower like subsequent studies.85 One possible 
explanation for this difference is that this study only analyzed boys with DMD ages 5.5-8.5 years 
old while other studies have included older children and adolescents in their study population. 
However, age effects on the concordance between parent-proxy and child-reported QoL have not 
yet been sufficiently analyzed. 
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Trends regarding how parent-proxy and child-reported QoL compare among the three core 
domains of HrQoL (physical, psychological, and social) provide more insight into how caregivers 
perceive the QoL of their children with DMD. Even when overall concordance is low, parents and 
their children with DMD generally have moderate to high agreement in regards to the child’s 
physical HrQoL. This is often the most agreed-upon aspect of HrQoL in children with DMD. 
Agreement regarding psychological and social HrQoL, however, tends to be significantly lower 
than physical HrQoL with caregivers sometimes underestimating their child’s perceived 
psychological HrQoL and other times overestimating it. These trends suggest that parents are more 
able to report on domains of HrQoL that they can see than they are able to report on less visible 
domains. Some studies have found that parent-proxy and child-reported HrQoL have moderate to 
high agreement when considering the topics of “Daily Activities” and “School Functioning,” 
further supporting the idea that parents of children with DMD are more able to report on aspects 
of HrQoL they can directly observe.11,14 
Although there are trends, the agreements between parent-proxy and child-reported QoL 
in each domain are still inconsistent, particularly in the psychosocial domain. Lim et al. 
hypothesized that some of these differences could be explained by differences in statistical 
methods.13 Most studies use the Student’s t-test, Pearson’s correlation coefficient, and Interclass 
Correlation Coefficient (ICC) when analyzing the data, but they can also be analyzed using a Rasch 
model which can capture both question difficulty and responder ability.13 Lim et al. surveyed boys 
with DMD and their caregivers using the PedsQLTM Version 4.0 (Generic Core Scale) and 
compared these methods of analysis. The results of the Rasch model-analysis indicated that there 
was less agreement regarding psychosocial HrQoL than physical HrQoL, and that more parents 
reported their child’s QoL lower than the child did.13 These results are consistent with those using 
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standard statistical methods. The Rasch model also revealed that 4 out of 23 individual items in 
the survey were reported differently between caregivers and the boys with DMD.13 Further use of 
the Rasch model could provide more information regarding specific differences between parent-
proxy and child-reported QoL.    
 There is a distinct lack in research regarding other factors that may influence caregiver 
perceptions of QoL in DMD. Social economic status, parent age, child age, and perceived personal 
QoL may all impact how caregivers of boys with DMD report the QoL of the boys. Future research 
on these and other factors will allow for a better understanding of the relationship between parent-
proxy and child-reported QoL.   
 In summary, there does seem to be differences between how boys with DMD perceive their 
QoL and how their parents perceive it, although these differences are not consistent across studies. 
Parents generally report lower QoL than the boys do. Boys and their parents typically have higher 
agreement regarding physical QoL compared to psychosocial QoL, suggesting that parents are 
more able to report on aspects of QoL that they can directly observe. More research is needed to 
determine factors that affect parent-child agreement of QoL in DMD.  
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3.0  MANUSCRIPT 
3.1 BACKGROUND 
Duchenne Muscular Dystrophy (DMD) is an X-linked neuromuscular disorder that causes 
proximal muscle weakness followed by progressive loss of muscle function.1 It is the most 
common genetic cause of muscular dystrophy and occurs in approximately 1/5,100-1/9,300 live 
births.6,26 In the current era of treatment, boys with DMD generally lose ambulation in their mid-
teenage years and die in early- to mid-adulthood, most often due to respiratory or cardiac 
complications.4,5 There is not yet a cure for DMD, but there are substantial clinical research trials 
investigating pharmaceuticals and other interventions to delay the onset of disease milestones and 
(potentially) cure DMD.6 These therapeutics may also impact perceived quality of life (QoL) for 
boys with DMD.  
 Within the last decade, as clinical research on DMD has expanded, there has been an 
increasing interest in assessing QoL for boys with DMD. This research has primarily focused on 
health-related quality of life (HrQoL), which The Center for Disease Control and Prevention 
(CDC) defines as the “perceived physical and mental health over time.”8 HrQoL thus consists of 
physical and psychosocial QoL. Although HrQoL is technically a subset of QoL, the two terms 
are often used interchangeably.  
Many of the early studies on HrQoL in DMD relied on parent-proxy reports to determine 
how the disease affects QoL. However, more recent research has suggested that parents of boys 
with DMD may actually underestimate how their children perceive their own QoL, indicating that 
QoL in DMD is higher than parents perceive.10–16 Research also suggests poor concordance 
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between child and parent-proxy reports regarding psychosocial QoL, with parents sometimes 
reporting lower psychosocial QoL than the children report and other times reporting 
higher.10,11,14,85 Physical QoL appears to be more consistent across child and parent proxy reports. 
Some have suggested that this means parents of boys with DMD are better able to report on aspects 
of HrQoL that they can directly observe.12 However, research continues to yield mixed results 
regarding participant and caregiver-reported QoL, and further analysis is needed to address these 
differences.  
Most of the research on QoL in DMD has focused on younger children with the disease. 
Although some studies have included adolescents in their cohort, there are very few studies that 
focus specifically on QoL in adolescent and/or adult populations.11,14 One study conducted by 
Uzark et al. separated the results of their study by age-groups. This study concentrated primarily 
on QoL in DMD compared to healthy individuals, so results between DMD age-groups were not 
directly assessed. Although these results were not compared statistically, it appears that 
participants in the 13-18 year age group reported lower physical and higher psychosocial QoL 
compared to participants in the 8-12 year age group. Caregivers of participants in the 13-18 year 
age group also reported lower physical health scores compared to the 8-12 year age group; 
however, unlike the participants, caregivers reported lower psychosocial QoL for the older 
children than the younger children.11 These results suggest that there may be age effects on HrQoL 
and indicate that the results of studies on children with DMD might not apply to adolescents with 
DMD.  
Researchers have also investigated other factors that could affect HrQoL for boys with 
DMD.  Some factors hypothesized to affect QoL include glucocorticoid use, loss of ambulation 
(LoA), inability to self-feed, and non-invasive respiratory support use. Those last three factors are 
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considered to be significant disease milestones and may be used as endpoints in clinical research 
trials. Research has demonstrated improved physical QoL with glucocorticoid use, although it is 
unclear if this translates to improved total QoL.11,14,86 Studies also suggest that LoA correlates with 
reduced physical QoL for boys with DMD but does not correlate with psychosocial QoL.10,80 There 
is also conflicting data regarding the use of non-invasive respiratory support, with some research 
identifying no correlation with QoL and some indicating that non-invasive respiratory support 
correlates with reduced total QoL.23,24 Although the interactions between disease milestones and 
QoL in DMD have been investigated, no causal relationships have been identified.  
  This study aims to determine if caregivers of boys with DMD perceive their child’s QoL 
the same as the children perceive their own QoL. This study also aims to determine if steroid use, 
time at LoA, utilization of non-invasive respiratory support, and inability to self-feed: 1) correlate 
with perceived QoL for boys with DMD in this study cohort, 2) correlate with caregiver 
perceptions of QoL of boys with DMD, or 3) correlate with differences between caregiver and 
participant reported QoL (if any). The data for this study was previously collected through the 
Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History 
Study (DNHS). The CINRG DNHS is the most comprehensive DMD natural history study to date. 
Between 2006-2016, over 400 boys and men with DMD participated in the study. The phenotypic, 
genotypic, and biomarker data collected through this study has helped to shape the perception and 
management of DMD.  
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3.2 METHODS 
This study was reviewed and approved as Exempt by the University of Pittsburgh Institutional 
Review Board (IRB) (Appendix). 
3.2.1 Study Population  
The data analyzed in this study was previously collected through the CINRG DNHS which 
recruited over 400 boys ages 2-30 years old with DMD from eight different countries and followed 
them yearly between 2006-2016. Information on the CINRG DNHS study methods, including 
study timeline, eligibility criteria, and exclusion criteria, is outlined in detail by McDonald et al. 
in 2013.5 The data used in the analysis for this study was chosen based on availability of matching 
participant and parent-proxy reports. Figure 2 outlines how the data was selected for analysis. Of 
the 440 participants who participated in the CINRG DNHS, 219 participants ages 11-17 years old 
completed the PedsTM QL 4.0 Generic Core Scale at least once, and 46 participants ages 11-17 
years old completed the PedsTM QL 3.0 Neuromuscular Module (NMM) during at least one study 
visit.  Two participants who completed the PedsQLTM 4.0 survey did not have corresponding 
parent-proxy surveys and were excluded from analyses. Eight participants who completed the 
PedsQLTM 3.0 survey did not have corresponding parent-proxy reports and were also excluded 
from analyses. This left 217 and 38 participant and parent-proxy pairs for the PedsQLTM 4.0 and 
PedsQLTM 3.0 surveys respectively. Since the surveys were administered at every study visit, most 
pairs had data from multiple visits. Only the first visit with complete participant and parent-proxy 
data was used for analysis.   
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Figure 2: Process for Selecting Data for Analysis 
 
The data used to analyze QoL at disease milestones was selected based on participant 
milestones and survey availability. Participants who reached the milestone during the survey were 
isolated for analysis. Participants were excluded from analysis if did not have survey data before 
or after the onset of the disease milestone. Reasons for missing data include: 1) the participant 
reached the milestone before entering the study, 2) the participant did not reach the milestone 
during the study, or 3) the surveys were not completed before or after the onset of the milestone. 
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3.2.2  Data Acquisition  
Upon IRB approval, a data request was sent to the team in charge of the CINRG DNHS 
data. Only the necessary data required for analysis in this study was requested. After the data 
request was accepted, the statistician compiled the requested data and provided a completely de-
identified data set for analysis.  
3.2.3 Health-Related Quality of Life Data 
The Pediatric Quality of Life Questionnaire (PedsQLTM) Version 4.0 Generic Core Scale 
and Version 3.0 Neuromuscular Module (NMM) were both used to assess HrQoL in adolescents 
with DMD. The PedsQLTM 4.0 Generic Core Scale is a 23-question self-report survey that 
measures four core dimensions of HrQoL: Physical Functioning, Emotional Functioning, Social 
Functioning, and School Functioning.20 These subscales are combined to reveal Total QoL. The 
PedsQLTM 3.0 NMM is a 25-question self-report survey that is broken down into three subscales: 
About my Neuromuscular Disease (NMD), Communication, and Family Resources.10 These 
subscales are combined to reveal Total QoL. The questions on both surveys ask how much of a 
problem certain tasks and activities have been for the participant over the last month. Participants 
and caregivers rated their responses on a Likert-type scale from 0-4, with 0 indicating that a task 
is never a problem and 4 indicating that a task is “almost always” a problem.  
Participants in the CINRG DNHS aged 11-17 years old competed the PedsQLTM 4.0 self-
report at every study visit. Caregivers of participants ages 5-17 simultaneously completed the 
PedsQLTM 4.0 parent-proxy survey. The PedsQLTM 3.0 NMM was not administered until 2012. 
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Once added to the study, participants in the CINRG DNHS and their caregivers completed the 
PedsQLTM 3.0 NMM in the same fashion as the PedsQLTM 4.0 Generic Core Scale.5 
3.2.4 Disease-Specific Milestones  
LoA, inability to self-feed, and use of non-invasive respiratory support were the chosen 
disease-specific milestones for analysis in this study. Participant and parent-proxy reports were 
compared before and after the onset of each event. LoA and first-reported use of non-invasive 
respiratory support were each defined as the visit at which the physical exam or interval medical 
history first identified the onset of each milestone. Inability to self-feed was defined as a Brooke 
Upper Extremity Scale score of 5 or 6. The Brooke Upper Extremity Scale is a validated 
measurement of upper extremity function used to evaluate disease progression in DMD. Function 
is rated on a scale of 1 to 6, with 1 being no loss of upper extremity function and 6 being complete 
loss of upper extremity function. A score of 5 is defined as an inability to raise the hands to the 
face, but continued ability to hold items in the hand.56 Glucocorticoid use was defined in two ways: 
1) use status at the time of the completed HrQoL survey and 2) visit at which the interval medical 
history first identified glucocorticoid use. 
3.2.5 Data Analysis  
For the participant and parent-proxy comparisons, only the first visit with complete 
participant and parent-proxy data was used for analysis. The total scores for each subsection of the 
survey were compared between participant and parent-proxy reports—responses for individual 
question on the surveys were not evaluated. There were sporadic missing responses across the 
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questionnaires which prevented subscales or total scores to be calculated for a few participant and 
parent-proxy pairs. This caused sample sizes to differ slightly across the subscales of each survey. 
Responses were also compared based on age (11-13 years old vs 14-17 years old) and 
glucocorticoid use. The age groups were chosen based on the average age of the study population.   
For disease milestones, the survey data collected at the first visit where the event is noted 
in the physical exam was compared to the data collected at the previous visit, as long as the 
previous visit occurred within 365 days of the event. The non-invasive respiratory support category 
is the only exception, with a couple of “before” data points occurring within 2 years (730 days) of 
the event. This exception was made to ensure a large enough cohort for analysis. There was no 
significant difference in results when these exceptions were omitted from analysis. Only the results 
of the PedsQLTM 4.0 survey were analyzed in relation to disease milestones. There were not 
enough survey responses from the PedsQLTM 3.0 NMM survey to apply to the milestone data.  
More caregivers completed the PedsQLTM 4.0 survey than participants, and there were 
many caregiver survey results surrounding disease milestones that did not have matching 
participant surveys. For this reason, parent-proxy data was analyzed in two ways for the disease 
milestones: 1) caregivers of the available participant survey results were analyzed, and 2) all 
available parent-proxy data was analyzed, regardless of matching participant data. 
The data was assessed for normality and outliers. All surveys were compared using two-
sided Paired t-tests. Correlation between overall participant and parent-proxy reports was 
performed using Pearson’s correlation.  
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3.3 RESULTS 
3.3.1 Participant Information 
The PedsQLTM 4.0 Generic Core Scale and the PedsQLTM 3.0 NMM surveys were 
administered to participants ages 11-17 years old and their caregivers. Participant demographics 
are outlined in Table 1. Of the 217 participants who completed the PedsQLTM 4.0, 160 (73.9%) 
were between the ages of 11-13 years old, and 57 (26.1%) were 14-17 years old at the time of 
survey completion. 102 (47.0%) of these participants were ambulatory. Of the 38 participants who 
completed the PedsQLTM 3.0 NMM, 20 (52.6%) were between the ages of 11-13 years old and 18 
(47.4%) were 14-17 years old at the time of survey completion. 18 (47.4%) of these participants 
were ambulatory.  Most participants with survey data were using glucocorticoids at the time of 
survey completion (71.0%, 81.6%). The participants who were using glucocorticoids were taking 
either prednisone, deflazacort, or prednisolone. The large majority of participants in both the 
PedsQLTM 4.0 and PedsQLTM 3.0 NMM survey cohorts were Caucasian (70.0%, 81.6%), followed 


















Table 1: Participant Demographics 
 
 
3.3.2  Comparison of Participant and Parent Proxy Reports  
Figure 3 shows the participant and parent-proxy results of the PedsQLTM 4.0 Generic Core 
Scale surveys. Overall, there was no significant difference between the Total QoL reported in the 
participant and parent-proxy surveys (p=0.35). However, participants reported higher Physical 
Functioning scores (p=0.003) and lower Emotional Functioning (p=0.049), Social Functioning 
(p<0.001), and School Functioning (p=0.022) scores than the parent-proxy reports (Table 2). 
 
 PedsQLTM 4.0 
Generic Core Scale 
PedsQLTM 3.0 
NMM 
 N=217 % N=38 % 
Race     
 Caucasian 152 70.0 31 81.6 
 Asian 40 18.4 4 10.5 
 Black 4 1.84 1 2.63 
 Pacific Islander 2 0.09 0 0.0 
 Other 19 8.75 2 5.26 
     
Ethnicity     
 Non-Hispanic 186 85.3 38 100 
 Hispanic 31 14.2 0 0.0 
      
Age Range (11-18)     
 11-13 160 73.9 20 52.6 
 14-18 57 26.1 18 47.4 
      
Ambulation     
 Ambulatory 102 47.0 18 47.4 
 Non-ambulatory 115 53.0 20 52.6 
      
Glucocorticoids     
 Use 154 71.0 31 81.6 
 Nonuse  63 29.0 7 19.4 
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Figure 3: PedsOLTM 4.0: Participant Results Compared to Parent-Proxy Results 
 
 
Table 2: PedsQLTM 4.0 Overall Participant and Parent-Proxy Results 




Difference (SE) P-value Correlation 
(r) 
Physical (n=215) 66.91 (23.71) 61.56 (28.91) 5.35 (1.80) 0.003* 0.51* 
Emotional (n=217) 34.09 (19.87) 36.26 (18.90) 2.17 (1.09) 0.049* 0.66* 
Social (n=217) 38.18 (18.84) 44.93 (19.14) 6.75 (1.31) <0.001* 0.48* 
School (n=208) 33.57 (18.00) 36.36 (19.61) 2.79 (1.21) 0.022* 0.57* 
Total (n=215) 46.36 (15.36) 47.17 (15.04) 0.817 (0.88) 0.354 0.64* 
SD= Standard Deviation, SE= Standard Error, *= p <0.05 
 
 
Figure 4 shows the participant and parent-proxy results of the PedsQLTM 3.0 
Neuromuscular Module surveys. Participants reported significantly higher Family Resources 
scores (p=0.005) and Total QoL compared to the parent-proxy reports (p=0.033). There was no 
significant difference between participant and parent-proxy reports regarding the About My 
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Figure 4: PedsQLTM 3.0 NMM: Participant Results Compared to Parent-Proxy Results 
 
 







Difference (SE) P-value Correlation 
(r) 
About my 
Neuromuscular Disease  65.36 (16.50) 63.69 (15.95) 1.67 (1.66) 0.305 0.82* 
Communication 63.37 (25.00) 62.39 (25.31) 0.99 (2.14) 0.647 0.86* 
Family Resources 69.31 (18.71) 60.79 (22.35) 8.52 (2.88) 0.005* 0.64* 
Total  65.92 (14.63) 62.97 (15.28) 2.95 (1.33) 0.033* 0.85* 
SD= Standard Deviation, SE= Standard Error, *= p <0.05 
3.3.3  Participant Age and QoL  
  Age-effects on reported QoL in the PedsQLTM 4.0 survey are outlined in Table 4. Older 
participants (14-18) reported higher Physical Functioning scores (p=0.017) and lower Social 
Functioning scores (p=0.022) than younger participants (11-13). There was no significant 











About My NMD Communication Family Resources Total
PedsQL 3.0TM Neuromuscular Module
Participant Results Parent-Proxy Results
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reported higher Total QoL for older participants than for younger participants (p=0.042). 
Caregivers of older participants also reported higher Physical Functioning scores (p=0.035) than 
caregivers of younger participants.  
 Compared to parent-proxy reports, older participants reported lower Total QoL scores 
(p=0.03). They also reported lower Emotional Functioning (p=0.02), Social Functioning 
(p=0.004), and School Functioning (p=0.006) scores than their parent-proxies. There was no 
difference between participant and parent-proxy reported Total QoL for younger participants. 
However, younger participants, reported higher Physical Functioning scores (p=0.009) and lower 
Social Functioning (p=0.004) than their parent-proxy reports.  
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Table 4: PedsQLTM 4.0 and Participant Age 
 Age Group 11-13 
Average (SD) 
n=160 





Physical      
 Participant Report  64.66 (24.41) 73.46 (20.38) 8.80 (3.67) 0.017* 
 Parent-Proxy Report  59.13 (28.31) 68.64 (29.73) 9.51 (4.48) 0.035* 
 Difference (SE) 5.53 (2.09) 4.82 (3.54)   
 P-Value 0.009* 0.180   
    
Emotional      
 Participant Report  34.14 (20.51) 33.95 (18.12) 0.196 (3.07) 0.949 
 Parent-Proxy Report  35.20 (19.36) 39.25 (17.36) 4.06 (2.91) 0.164 
 Difference (SE) 1.05 (1.25) 5.31 (2.21)   
 P-Value 0.402 0.020*   
     
Social      
 Participant Report  39.92 (19.26) 33.29 (16.82) 6.63 (2.88) 0.022* 
 Parent-Proxy Report  45.23 (19.00) 44.08 (19.69) 1.15 (2.96) 0.699 
 Difference (SE) 5.30 (1.45) 10.79 (2.83)   
 P-Value 0.004* 0.004*   
     
School      
 Participant Report  34.06 (19.62) 33.77 (15.29) 0.292 (2.92) 0.921 
 Parent-Proxy Report  35.25 (19.58) 39.58 (19.52) 4.36 (3.09) 0.161 
 Difference (SE) 1.59 (1.43) 6.20 (2.16)   
 P-Value 0.269 0.006*   
     
Total      
 Participant Report  46.01 (16.16) 47.08 (12.92) 0.977 (2.39) 0.683 
 Parent-Proxy Report  45.94 (14.87) 50.69 (15.11) 4.75 (2.32) 0.042* 
 Difference (SE) 0.336 (1.03) 3.61 (12.58)   
 P-Value 0.745 0.036*   
 
 
Age effects on the PedsQLTM 3.0 survey are listed in Table 5. There was no significant 
difference in reported Total QoL between younger and older participants. Caregivers of younger 
participants reported higher About My NMD scores than caregivers of older participants 
(p=0.016). Younger participants also reported higher About my NMD scores than older 
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participants, although this result was not statistically significant (p=0.111). Participants in the 11-
13 age group reported significantly higher Family Resources scores than their caregivers 
(p=0.003). This difference was not seen with participants in the 14-17 age group and their 
caregivers. 
Table 5: PedsQLTM 3.0 NMM and Participant Age 
  Age Group 11-13 
Average (SD) 
n=20 





About NMD      
 Participant Report  69.42 (14.19) 60.85 (18.08) 8.57 (5.24) 0.111 
 Parent-Proxy Report  69.52 (15.14) 57.23 (14.61) 12.29 (4.84) 0.016* 
 Difference (SE) 0.099 (1.75) 3.63 (2.74)   
 P-Value 0.956 0.204   
    
Communication      
 Participant Report  63.75 (17.79) 62.96 (31.73) 0.787 (8.23) 0.924 
 Parent-Proxy Report  61.04 (18.15) 63.89 (31.96) 2.85 (8.32) 0.734 
 Difference (SE) 2.71 (2.67) 0.926 (3.43)   
 P-Value 0.324 0.790   
     
Family Resources      
 Participant Report  73.50 (19.06) 64.65 (17.67) 8.85 (5.98) 0.158 
 Parent-Proxy Report  61.00 (22.10) 60.56 (23.26) 0.44 (7.36) 0.952 
 Difference (SE) 12.50 (12.62) 4.10 (5.09)   
 P-Value 0.003* 0.432   
     
Total      
 Participant Report  69.58 (12.05) 61.84 (16.43) 7.74 (4.64) 0.104 
 Parent-Proxy Report  66.80 (13.93) 58.70 (15.95) 8.10 (4.85) 0.103 
 Difference (SE) 2.78 (1.43) 3.14 (2.36)   




3.3.4 Glucocorticoid Use and QoL  









Physical      
 Participant Report  80.24 (18.88) 61.63 (24.0) 18.60 (3.36) <0.001* 
 Parent-Proxy Report  71.98 (31.99) 57.43 (27.06) 14.55 (4.27) <0.001* 
 Difference (SE) 8.26 (3.84) 4.20 (2.00)   
 P-Value 0.036* 0.037*   
    
Emotional      
 Participant Report  33.17 (21.10) 34.47 (19.40) 1.29 (2.98) 0.665 
 Parent-Proxy Report  33.93 (20.37) 37.22 (18.24) 3.29 (2.82) 0.246 
 Difference (SE) 0.754 (2.43) 2.75 (1.18)   
 P-Value 0.757 0.022*   
     
Social      
 Participant Report  37.00 (19.51) 38.66 (18.59) 1.66 (2.82) 0.558 
 Parent-Proxy Report  43.33 (22.02) 45.57 (17.87) 2.24 (2.86) 0.435 
 Difference (SE) 6.32 (2.51) 6.92 (1.54)   
 P-Value 0.014* <0.001*   
     
School      
 Participant Report  36.03 (21.56) 33.21 (17.28) 2.83 (2.86) 0.325 
 Parent-Proxy Report  37.55 (23.24) 35.95 (18.17) 1.50 (3.07) 0.626 
 Difference (SE) 2.90 (2.21) 2.75 (1.44)   
 P-Value 0.194 0.059   
     
Total      
 Participant Report  50.86 (14.63) 44.58 (15.32) 6.27 (2.29) 0.007* 
 Parent-Proxy Report  50.66 (16.14) 45.80 (14.41) 4.86 (2.26) 0.033* 
 Difference (SE) 0.20 (1.62) 1.22 (1.04)   
 P-Value 0.90 0.25   
 
Analysis of the effects of glucocortiocoid use and QoL was only performed on the data 
collected through the PedsQLTM 4.0 survey. The majority of the participants who completed the 
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PedsQLTM NMM were taking glucocorticoids, and there were not enough participants in the non-
glucocorticoid group to make an appropriate comparison (n=7). 
At the time of survey completion, there was no difference between participant and parent-
proxy reports of Total QoL from the PedsQLTM 4.0 survey, regardless of glucocorticoid use status 
(Table 6). However, both participants and parent-proxy surveys reported improved Total QoL for 
participants not using glucocorticoids than participants using glucocorticoids (p=0.007, p=0.033). 
When results were broken down by subscales of QoL, both participant and parent-proxy surveys 
reported increased Physical Functioning scores for participants not using glucocorticoids than for 
participants using glucocorticoids at the time of the survey (p<0.001, p<0.001). Over 50% of 
participants not using glucocorticoids reported a Total QoL score of 80 or above. Participants also 
reported higher Physical Functioning (p=0.036, p=0.037) and lower Social Functioning (p=0.014, 
p<0.001) scores than parent-proxy surveys, regardless of glucocorticoid use status.  Participants 
using glucocorticoids reported decreased Emotional Functioning scores compared to parent-proxy 
reports (p=0.022). This difference was not seen in participants not using glucocorticoids. School 
Functioning did not differ significantly by glucocorticoid use status.  
 
Table 7: Parent-Proxy Reports Before and After Glucocorticoid Use 
(n=37) Average (SD) Difference (SE) P-Value 
       Before 35.74 (15.94) 1.28 (2.27) 0.577        After 34.46 (16.17) 
 
 Survey responses were also compared before and after the start of glucocorticoid use (Table 
7). There was no significant difference in parent-proxy reported Total QoL before and after starting 
glucocorticoids. There was insufficient data to analyze participant responses (n=2).  
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3.3.5 Loss of Ambulation and QoL 
Table 8 outlines participant and parent-proxy reported Total QoL before and after LoA. 
“Parent-Proxy Report” refers to the caregivers of the participants while “All Parent-Proxy 
Reports” refers to the total available caregiver survey results for this milestone. Average age of 
LoA was 12.92 years old. Of all the parent proxy surveys collected, caregivers reported increased 
Total QoL after participants reached LoA compared to before LoA (p=0.045). Participants and 
their corresponding parent-proxy surveys also generally reported increased Total QoL after LoA, 
although this difference was not statistically significant. There was no significant difference 
between participant and parent-proxy reported Total QoL before or after LoA (Table 9). 
Table 8: PedsQLTM 4.0 Total QoL and Loss of Ambulation 
 Average (SD) Difference (SE) P-Value 
Participant Report (n=25)    
       Before 43.52 (12.42) 
3.10 (1.95) 0.125 
       After 46.62 (11.73) 
Parent-Proxy Report (n=24)     
       Before 44.22 (12.26) 
5.03 (3.54) 0.169        After 49.25 (15.32) 
All Parent-Proxy Reports (n=59)    
       Before 46.07 (11.49) 3.69 (1.80) 0.045* 
       After 49.76 (13.18)   
  
 
Table 9: PedsQLTM 4.0 QoL and Loss of Ambulation-Participant and Parent-Proxy Comparison 
 Participant Average (SD) Parent-Proxy Average (SD)  P-Value  
Before (n=24) 43.71 (12.66) 44.22 (12.26) 0.841 
After (n=24) 46.44 (15.32) 49.25 (15.32) 0.281 
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3.3.6  Loss of Self-Feeding and QoL 
Table 10 outlines participant and parent-proxy reported Total QoL before and after the 
participant lost the ability to self-feed. Average age of loss of self-feeding (Brooke scale of 5 or 
higher) was  15.58 years old. Interestingly, participants reported improved Total QoL after losing 
the ability to lift their hands to their face (p=0.044).  Parent-proxy reports also generally reported 
increased Total QoL after this milestone was reached, although these results were not statistically 
significant. Participants tended to report higher Total QoL than their corresponding parent-proxy 
surveys, but again this result was not statistically significant (Table 11).  
 
Table 10: PedsQLTM 4.0 Total QoL and Inability to Self-Feed 
 Average (SD) Difference (SE) P-Value 
Participant Report (n=29)    
       Before 43.70 (14.59) 
5.01 (2.38) 0.044* 
       After 48.71 (12.79) 
Parent-Proxy Report (n=27)     
       Before 41.87 (17.92) 
2.97 (2.98) 0.327        After 44.8. (19.88) 
All Parent-Proxy Reports (n=38)    
       Before 44.60 (17.52) 
2.00 (2.15) 0.367        After 46.57 (19.65)  
 
 




Average (SD)  
Difference (SE) P-Value  
Before (n=29) 44.44 (14.34) 41.37 (17.43) 3.06 (2.67) 0.261 




3.3.7 Use of Non-Invasive Respiratory Support and QoL  
Table 12 outlines participant and parent-proxy reported Total QoL before and after the 
participant began using non-invasive respiratory support. There was no significant difference 
between participant reported Total QoL before and after the onset of non-invasive respiratory 
support use. The same was true for the parent-proxy reported Total QoL. There was also no 
significant difference between participant and parent-proxy reported Total QoL before or after the 
participant began using non-invasive respiratory support (Table 13). 
 
Table 12: PedsQLTM 4.0 Total QoL and Use of Non-Invasive Respiratory Support 
 Average (SD) Difference (SE) P-Value 
Participant Report (n=16)    
       Before 46.14 (12.72) 
1.09 (2.59) 0.679 
       After 47.23 (12.55) 
Parent-Proxy Report (n=16)     
       Before 46.84 (15.79) 
2.34 (3.48) 0.511        After 49.19 (8.48) 
All Parent-Proxy Reports (n=38)    
       Before 46.69 (15.04) 2.87 (2.68) 0.297 
       After 49.56 (9.09)   
 
 





Average (SD)  
Difference (SE) P-Value  
Before (n=16) 46.14 (12.72) 48.04 (13.44) 1.90 (2.44) 0.450 
After (n=16) 47.17 (12.52) 49.15 (8.48) 2.02 (2.37) 0.408 
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3.4 DISCUSSION 
3.4.1 QoL in Adolescents with DMD 
The two surveys evaluated in this study revealed interesting and sometimes conflicting 
results. Overall, the responses in every section of the PedsQLTM 4.0 survey were lower than those 
previously reported by healthy peers.11 The PedsQLTM 4.0 survey showed no difference between 
participant and parent-proxy reported Total QoL, suggesting that parents of adolescents with DMD 
perceive their sons’ Total QoL the same as the sons do. However, participants reported 
significantly higher Total QoL on the PedsQLTM 3.0 NMM survey compared to their caregivers, 
which contradicts the findings from the other survey. Upon investigation of the survey subscales, 
it appears the difference in Total QoL reported in the PedsQLTM 3.0 NMM was primarily driven 
by participant reports regarding family resources. The boys in this population did not perceive as 
many problems regarding family resources as their parents, which suggests that adolescents with 
DMD are either less aware of or less concerned with money problems than their parents. This is 
not unexpected since parents manage household finances and are likely more aware of the costs 
associated with DMD treatments than their children.  
There were also differences in perception regarding the subscales of the PedsQLTM 4.0 
survey, with participants reporting higher physical QoL and lower psychosocial QoL in all three 
domains (emotional, social, and school) than their parents. The physical QoL results are somewhat 
surprising in the context of previous research, which has indicated that boys with DMD and their 
caregivers generally have similar perceptions regarding physical QoL.12 One possible reason for 
the discordant findings in this study is the age-group of the participants. Most research on QoL in 
DMD has either been focused on children or has grouped adolescents and children into the same 
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analysis.10,12,21,25,64,85 This study focuses on boys ages 11-17, and the experiences of an adolescent 
may be quite different than the experiences of a child. This could also explain why this study 
identified that participants reported significantly lower psychosocial QoL when other studies have 
not.11,14 Although age effects on QoL have not been sufficiently studied in DMD, it’s possible that 
age could explain these differences in results. Interestingly, there was no significant difference in 
participant and parent-proxy reports from the “About My Neuromuscular Disease” subsection of 
the PedsQLTM 3.0 NMM. This section focuses on physical aspects of neuromuscular disorders, so 
it should theoretically mirror the physical QoL results from the PedsQLTM 4.0 survey. Since the 
sample size for the PedsQLTM 3.0 NMM was smaller, it is possible that there was not enough data 
to detect the significant difference seen in the PedsQLTM 4.0 survey. It is also possible that the 
PedsQLTM 4.0 survey does not accurately address QoL in DMD. The physical QoL questions on 
the PedsQLTM 3.0 NMM survey were developed specifically for those with neuromuscular 
disorders and addresses appropriate physical complications such as difficulty using hands or 
difficulty breathing. In contrary, the physical QoL questions on the PedsQLTM 4.0 survey ask about 
more general tasks including walking, running, and lifting heavy objects—assessments that are 
largely inappropriate for non-ambulatory boys with DMD who no longer attempt to perform those 
tasks. Given that approximately half of this study population was non-ambulatory and boys with 
DMD generally lose ambulation during adolescence, it is possible that the physical QoL questions 
on the PedsQLTM 4.0 survey are not appropriate for adolescents with DMD and may not accurately 
capture physical QoL in this population.  
If participants or caregivers perceived a question as being inappropriate or were unable to 
answer the question, they had the option to leave the question blank. Blank questions could impact 
the total scores for each section since the total score equals the scores for each question divided by 
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the total number of questions answered for that section. A brief analysis of the responses to 
individual questions revealed minimal impact of skipped questions. The physical QoL questions 
on the PedsQLTM 4.0 survey that participants skipped the most were the two related to walking 
(4.15%) and running (3.69%). This matches our expectations given DMD disease progression. 
These two questions were also the most common physical QoL questions skipped by caregivers, 
although fewer caregivers skipped these two questions than participants (2.76%, 1.84%)  It is 
unlikely that the skipped questions significantly impacted total physical QoL in this study. Further 
analysis regarding the scores for each question could better elucidate the appropriateness of those 
measures.   
 To further assess possible effects of age, data collected from boys ages 11-13 were 
compared to data collected from boys ages 14-17. Participants in the older age group reported 
lower social QoL compared to participants in the younger group suggesting that perceived social 
QoL decreases as age increases for adolescents with DMD. Older participants also reported 
significantly lower Total QoL on the PedsQLTM 4.0 survey than their caregivers. This seems to 
have been driven by differences in perceived psychosocial QoL since participants reported lower 
scores across emotional, social, and school-functioning domains compared to their caregivers, 
suggesting that older adolescents perceive their psychosocial QoL lower than their parents do. If 
it is true that the discrepancy between perceived psychosocial QoL exists for older adolescents but 
not younger adolescents, then this could provide one explanation for the conflicting research 
regarding participant and caregiver-perceived psychosocial QoL. Younger participants in this 
study also reported higher physical QoL than their caregivers, suggesting a discrepancy in 
perceived physical QoL between caregivers and younger adolescents with DMD. This contradicts 
the previous studies that have identified moderate to high correlations between participant and 
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parent-proxy reported physical QoL, although, as stated previously, most previous research has 
included both children and adolescents in analysis, so the differences captured in this study may 
be unique to adolescents with DMD. 12  
Unlike with the PedsQLTM 4.0 survey, there was no significant difference in Total QoL 
reported between older and younger participants in the PedsQLTM 3.0 NMM. This could be due to 
the fact that the PedsQLTM 3.0 NMM emphasizes disease-specific physical effects on QoL (17 of 
the 25 questions relate to physical QoL) and does not fully assess the social and emotional impacts 
of disease.  
 Results from the PedsQLTM 4.0 survey were also separated by glucocorticoid use at the 
time of the survey completion. Participants using glucocorticoids reported significantly lower 
emotional QoL compared to parent proxy reports. This difference was not observed with 
participants who were not using glucocorticoids which could mean that caregivers of boys with 
DMD perceive that glucocorticoids have a more positive effect on emotional QoL than the boys 
perceive.   
Surprisingly, both participants and caregivers reported that boys using glucocorticoids had 
lower total QoL compared to boys not using glucocorticoids. Even more surprising, this result 
seems driven entirely by the physical reports, for which both participants and caregivers reported 
higher physical QoL for participants not using glucocorticoids than for participants using 
glucocorticoids. Glucocorticoids are known to delay the onset of disease milestones and are 
thought to improve physical QoL in DMD.14,44 The unexpected trend was also observed between 
the age groups, with both participants and caregivers reporting increased physical QoL on the 
PedsQLTM 4.0 survey with older ages. Given the progressive nature of DMD, these results seem 
counterintuitive, especially when research generally shows a negative correlation between physical 
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QoL and age.11,14,16 Analysis of the data revealed no significant outliers driving the results. In fact, 
physical QoL was consistently the highest rated subscale of QoL regardless of age or 
glucocorticoid use.  
One possible explanation for the difference in Total QoL based on glucocorticoid status is 
that adolescents with DMD who are taking steroids may perceive a burden of treatment not 
experienced by adolescents who are not taking steroids. Treatment burden is caused by the work 
needed to maintain the treatment, which includes the burden of patient understanding, time, 
frequency, and effort required to pursue and manage the treatment.87 Side-effects of treatment 
could also be considered in treatment burden. One study conducted in Italy revealed that 
individuals living with rare diseases are not only impacted by the significant side-effects of 
treatment, they feel restricted by the consistent need for treatment and perceive that their 
treatments, although necessary, limit their freedom.88 Treatment burden has also been identified 
as a problem with chronic conditions like advanced heart failure.87 Given the significant side 
effects and repetitive nature of glucocorticoid therapy, it is possible that the adolescents in this 
study were negatively impacted by their therapy, and this was reflected in the Total QoL results. 
Another possibility is that the participants taking glucocorticoids may expect to experience 
improved physical abilities because they are taking a medicine. However, glucocorticoids merely 
delay the time to reach disease milestones, so adolescents taking steroids may not perceive a 
benefit, especially as they continue to lose muscle function. This could lead to disappointment, 
which could then lead them to perceive worse physical and overall QoL compared to adolescents 
not taking glucocorticoids.  
Another possible explanation for the unexpected physical QoL results for adolescents 
taking steroids lays in the nature of the PedsQLTM 4.0 survey questions. If it is true that the 
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PedsQLTM 4.0 survey does not appropriately capture physical QoL for adolescents with DMD, this 
could have influenced the results related to glucocorticoid use. Unfortunately, analysis of 
glucocorticoid use and QoL could not be performed using the PedsQLTM 3.0 NMM for comparison 
since there were too few steroid non-users to perform an appropriate comparison.   
Another interesting finding is that participants reported lower social QoL scores than their 
caregivers regardless of age and glucocorticoid status. Although there was moderate correlation 
between participant and parent-proxy reports, this was the lowest correlation observed for all 
scales in the PedsQLTM 4.0 survey. This suggests that adolescents with DMD may experience 
social deficits that their parents do not perceive, and that interventions targeting social QoL could 
help improve the total QoL for adolescents with DMD. Previous research comparing social QoL 
perspectives for boys with DMD ages 5-18 years old has also identified moderate agreement 
between participant and parent-proxy reports; however, participants in these studies appear to 
report higher average social QoL than their caregivers.10,14,25 This trend was even seen in Uzark et 
al’s study which isolated adolescents with DMD for analysis, although the participant and parent-
proxy social QoL results were not directly compared so it is unclear if there was a significant 
difference.11 The social QoL results in this study are also generally lower than those reported in 
previous studies using the same survey method.10,11,14,25 Given that the data used in this study came 
from an international cohort, it is possible that adolescents in this study have different perceptions 
regarding their social QoL than those in previous studies.  
3.4.2 QoL Results at Disease Milestones 
LoA, inability to self-feed, and use of non-invasive respiratory support were the chosen 
disease milestones for analysis in this study because of their significance within the timeline of 
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disease progression and effect on medical management. Unfortunately, many of the adolescents 
who completed the PedsQLTM 4.0 survey had already reached one or more of the disease 
milestones by the time of their first survey, meaning the before-and-after comparisons could not 
be performed for these participants. This means the sample sizes for these analyses were smaller 
and the power to find any differences is reduced.  
No significant differences were found for participants reported Total QoL before and after 
LoA. This finding is congruent with prior studies that have not identified a difference in perceived 
Total QoL between participants using wheelchairs and those not using wheelchairs.10,11 These 
results support the hypothesis that there is not a causal link between QoL and LoA. Caregivers, on 
the other hand, reported increased QoL after the participants lost ambulation, although this result 
was not replicated in the subset of caregivers who had comparable participant surveys. Davis et al. 
2010 assessed parent-proxy reported QoL and LoA (n=12) and found no effect of wheelchair use 
on parent-proxy reports. Given the results of this study, it is possible that previous studies have 
been too small to identify a significant difference.  
Surprisingly, participants reported increased QoL after reaching the inability to self-feed 
compared to before losing this ability. This contradicts previous research which has suggested that 
the Brooke scale (the scale used to quantify inability to self-feed in this study) does not correlate 
with perceived QoL in boys with DMD.82 This finding is also incongruent with discussions held 
at an advocacy conference hosted by Parent Project Muscular Dystrophy (PPMD) in March of 
2018. Surveys administered during “The Duchenne Patient-Focused Compass” session revealed 
that boys with DMD ages 11-17 years old are significantly impacted by the inability to raise their 
arms above their head.89 Survey respondents even reported that if a therapeutic intervention could 
preserve one ability in this age group, it would be most important to maintain the ability to self-
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feed. This sentiment was also expressed by adults with DMD.89 It is important to note, however, 
that the adolescent survey responses were completed by both boys with DMD and their caregivers, 
so the findings may not completely reflect the experiences of the boys. Still, given the opinions 
expressed at this conference, it is surprising that participants in this study reported higher QoL 
after losing the ability to self-feed. Although this result may be novel and significant, it could also 
be a product of the abnormal physical QoL reports observed in this study and may not accurately 
reflect the experiences of the adolescents. More research is needed to determine if and how the 
inability to self-feed affects QoL in DMD.   
There were no significant differences in participant or parent-proxy reports before and after 
use of non-invasive respiratory support. This is consistent with the findings of Kohler et al. 2005. 
However, the Kohler study utilized an adult survey to assess children with DMD, so it is difficult 
to properly interpret these findings in relation to the current study.23 Another study has found that 
non-invasive respiratory support correlates with decreased QoL, but the cohort in this study 
consisted of children with DMD and children with other neuromuscular disorders, so it is difficult 
to determine if the results extend to adolescents with DMD. The findings in this study could mean 
that non-invasive respiratory support use does not impact perceived QoL in DMD.24 It is also 
possible that the timespan between the before and after surveys was too short to detect any 
perceived differences.  
3.4.3 Survey Selection  
The CINRG DNHS administered multiple different surveys to participants and their 
caregivers to capture QoL data. The PedsQLTM 4.0 Generic Core Scale was selected for primary 
analysis in this study because previous research on QoL in DMD has often used the PedsQLTM 4.0 
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scale. This means the results of this study can be more directly compared to the results of previous 
studies. One limitation of this survey is it was developed for all children regardless of health status. 
Other surveys such as the Pediatric Orthopedic Society of North America (POSNA) Pediatric 
Musculoskeletal Functional Health Questionnaire (also referred to as the Pediatric Outcomes Data 
Collection Instrument or PODCI)67,68 and the PedsQLTM 3.0 NMM were developed to assess 
musculoskeletal and neuromuscular HrQoL. This study also analyzed the results of the PedsQLTM 
3.0 NMM to see how responses differed between the two PedsQLTM surveys. Based on the findings 
outlined earlier in the discussion, it appears as though the PedsQLTM 4.0 has a more robust 
assessment of psychosocial QoL than the PedsQLTM 3.0 NMM; however, the PedsQLTM 4.0 might 
not be the most appropriate tool for assessing physical QoL in adolescents with DMD. Previous 
research has suggested incorporating both of these surveys to gain a more in-depth assessment of 
QoL in DMD.10 Given the strengths and weaknesses of these two surveys, it would be reasonable 
to include both surveys when assessing QoL in DMD as this study has done.   
3.4.4 Limitations and Directions for Future Research  
Some of the limitations of this study have been outlined already. A number of the outcomes 
in this study relied on the PedsQLTM 4.0 Generic Core Scale for analysis. Although this scale has 
been validated for use in DMD cohorts10, this survey might not be appropriate for analyzing 
physical QoL for adolescents with DMD, and other survey measures may better capture QoL in 
this study population. Future research could compare the results from this study to those of other 
surveys administered during the CINRG DNHS (like the POSNA) to better elucidate how 
adolescents with DMD and their caregivers perceive the boys’ QoL. Future research could also 
assess differences in responses between participants and caregivers in different geographical 
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regions. Since the CINRG DNHS was an international study, the overall survey results could be 
impacted by differing QoL perspectives in different countries. Participants in the CINRG DNHS 
also completed these surveys at multiple study visits, meaning there is longitudinal data that could 
be explored. Although the scope of this study does not include a longitudinal analysis, a cursory 
overview of the PedsQLTM 4.0 survey data suggests that participant and parent-proxy reported 
Total QoL is inconsistent over time. A robust longitudinal analysis of QoL in DMD has not yet 
been attempted. This analysis could provide more insight into the conflicting results between QoL 
in different age-groups.  
 Results in this study were separated by age-group, but another way to assess QoL over the 
lifespan in DMD is to break down the results by the participants’ ambulatory stages. More recent 
studies investigating QoL in DMD have separated the results by ambulatory stage.16,83 Their results 
clearly identified an inverse correlation between total QoL and ambulatory status.16,83 Although it 
is assumed that older boys with DMD are at later ambulatory stages, new and emerging 
therapeutics are delaying the progression of disease and may blur the lines between age and 
ambulatory status. Future research could continue to assess how ambulatory stage correlates with 
total QoL as well as the subscales.  
 Analysis of disease milestones in this study was also limited by small sample sizes since 
many participants either reached the milestone(s) before entering the study or did not reach them 
during their time in the study. This means there was less statistical power to detect differences in 
survey responses and the data was more prone to random error. Further research is needed to 
determine what causal effects (if any) the disease milestones analyzed in this study have on QoL. 
Finally, research on QoL in adolescents with DMD is limited, with most studies grouping 
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adolescents with children for analysis. The results of this study warrant further investigation into 
QoL in adolescents with DMD.  
3.5 CONCLUSION 
This study shows that there are differences between adolescent and caregiver-perceived QoL with 
DMD. Caregivers may underestimate their child’s physical QoL and overestimate their child’s 
psychosocial QoL, suggesting that adolescents with DMD have psychosocial difficulties not 
noticed by their caregivers. Future research on the topic should continue to ascertain both 
participant self-report and parent-proxy reports to better understand these perceptions.  
This study also suggests that adolescents with DMD have different perceptions regarding 
their QoL than younger children with DMD, and more research is needed to further assess these 
differences. Research on adolescents is lacking, and future research could help determine strategies 
to improve QoL specifically for adolescents with DMD. This study, for example, suggests that 
interventions aimed at improving social QoL could have a significant impact on QoL for 
adolescents with DMD. As therapeutics develop and the progression of disease slows, adolescents 
with DMD may retain more physical abilities than before. This means it will be important to 
continue to assess QoL in adolescents as their perceptions will likely change over time. 
Finally, this study suggests that adolescents taking glucocorticoids may experience burden 
from the daily medicine and may have more negative perceptions regarding their physical QoL 
than suggested given previous research. LoA and use of non-invasive respiratory support does not 
correlate with changes in HrQoL for adolescents with DMD; however, it is possible that the sample 
sizes were too small to detect a difference, as evidenced by the total caregiver responses at the 
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time of LoA. Participants in this study also reported increased QoL after losing the ability to self-
feed. Although this could suggest that adolescents with DMD perceive reduced burden after losing 
the ability to feed themselves, this contradicts anecdotal evidence. Further research on the effects 
of disease milestones on QoL in DMD is needed, and researchers should strive to incorporate 
larger sample sizes and appropriate surveys to better detect any differences.   
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4.0  RESEARCH SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH 
Although this thesis project focused specifically on adolescents with DMD and their caregivers, 
the findings of the study have the potential to extend beyond this population. Rare-disease 
researchers, for example, can use the findings from this study to better inform their own research 
projects. The FDA states that QoL measures are an important part of clinical research and should 
continue to be incorporated into research trials, especially those related to chronic and rare-
diseases.58 Given the importance of QoL measures in clinical research, it is crucial that researchers 
select the most appropriate QoL surveys for their population. This study helps to demonstrate that 
some QoL surveys may capture more useful information than others. It is important that DMD 
researchers and investigators studying other rare and/or debilitating diseases utilize appropriate 
assessments to ensure their QoL measurements reflect the experiences of their participants.  
 QoL research in DMD and other rare diseases also contributes to the broader field of public 
health. Public health incorporates ten essential services to improve population health and prevent 
negative health outcomes.90 This thesis project applies to many of the core services of public 
health. The first service is, of course, research. Research is a key component of public health and 
is incorporated through every step from initial assessment of a public health problem to the final 
evaluation of the proposed solution. The research in this project contributes to the “Monitor 
Health” service which is part of the overall assessment of a public health problem. By evaluating 
QoL in adolescents with DMD, this project helps monitor one aspect of health in DMD and 
provides information needed to assess the health in individuals with DMD and rare-diseases in 
general. This project also contributes to the “Diagnose and Investigate” service—the next step in 
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assessing a health problem. By analyzing the effects of age, glucocorticoid use, and disease 
milestones on QoL, this study investigates factors that may impact QoL in DMD and contributes 
to the knowledge needed to propose interventions to improve QoL for boys with DMD. Finally, 
by comparing the two different survey methods and assessing their use in the DMD population, 
this project contributes to the “Evaluation” service of public health. This study suggests that the 
PedsQLTM 4.0 survey might not be the most appropriate measurement to assess physical QoL in 
DMD and other diseases with a significant physical impact, but the PedsQLTM 3.0 NMM might 
not capture certain aspects of psychosocial QoL. Choosing the right survey to assess QoL is crucial 
for developing policies and interventions to improve population health and QoL, and by evaluating 
these surveys in the context of adolescents with DMD, this study helps to guide proper use of these 
surveys in DMD and other populations.  
 Since DMD is a genetic disease, genetic counselors in a variety of specialties may have the 
opportunity to work with a family impacted by DMD. Some genetic counselors work in 
neuromuscular clinics where regularly follow families with DMD and other neuromuscular 
disorders over many years. These counselors have the unique opportunity to help individuals and 
families cope and adapt to the changes experienced throughout the course of the disease. Genetic 
counselors can use the findings in this study to educate parents about the QoL for adolescents with 
DMD. This could help parents of younger children with DMD anticipate the QoL for their child 
in the future and could help parents of adolescents with DMD better understand their sons’ 
experiences. Genetic counselors who are part of the care team for an adolescent with DMD can 
also use the information provided in this study to better assess the psychosocial state of the 
adolescent. For example, genetic counselors could consider asking targeted questions about their 
patient’s social life and, if needed, suggest strategies to improve social QoL.  
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Not all genetic counselors work with individuals and families impacted by DMD. Still, 
genetic counselors can use the results from this project to inform their own counseling for different 
genetic diseases. This study identified that there are significant differences between QoL perceived 
by the adolescents with DMD and their caregivers. Such differences likely exist for other diseases, 
and genetic counselors could incorporate this knowledge when working with children and 
adolescents with various genetic diseases and their parents.  
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